Tositumomab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CD20 |
| Clinical data | |
| Trade names | Bexxar |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a609013 |
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C6416H9874N1688O1987S44 |
| Molar mass | 143859.7 g/mol g·mol−1 |
  (what is this?) (verify) | |
Tositumomab is a drug for the treatment of follicular lymphoma. It is an IgG2a anti-CD20 monoclonal antibody derived from immortalized mouse cells.
Tositumomab is applied in a sequential infusion followed by iodine (131I) tositumomab, which is the same antibody covalently bound to the radionuclide iodine-131 (131I).[1] 131I emits both beta and gamma radiation and decays with a half-life of 8 days.
Clinical trials have established the efficacy of the tositumomab/iodine (131I) tositumomab regimen in patients with relapsed or chemotherapy/rituxan refractory follicular lymphoma.
This drug combination is manufactured by Corixa (now GlaxoSmithKline). It sells in the U.S. under the trade name Bexxar. Sale of the drug will be discontinued in February 2014.[2]
Bexxar was developed by Mark Kaminski and Richard Wahl.[citation needed][clarification needed]
There is some evidence that it may cause a smaller decrease in platelet counts than ibritumomab tiuxetan does.[3]
References
- ^ Bexxar Prescribing Information
- ^ "Why Good Drugs Sometimes Fail: The Bexxar Story".
- ^ Jacene HA, Filice R, Kasecamp W, Wahl RL (2007). "Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice". J. Nucl. Med. 48 (11): 1767–76. doi:10.2967/jnumed.107.043489. PMID 17942813.
{{cite journal}}: CS1 maint: multiple names: authors list (link)
External links
- Bexxar regimen entry in the public domain NCI Dictionary of Cancer Terms
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |